Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galli, M
Right arrow Articles by Barbui, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galli, M
Right arrow Articles by Barbui, T
Haematologica, Vol 90, Issue 12, 1643-1649
Copyright © 2005 by Ferrata Storti Foundation

Evaluation Studies

Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma

M Galli, A Nicolucci, M Valentini, M Belfiglio, F Delaini, C Crippa, AM Barbui, U Giussani, A Rambaldi, and T Barbui

Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy. monicagalli@virgilio.it

BACKGROUND AND OBJECTIVES: Clinical trials have shown that high dose chemotherapy (HDT) with peripheral stem cell autotransplantation is presently the best treatment for patients with symptomatic multiple myeloma (MM). In the context of an outcomes research project, we analyzed the feasibility of this strategy in clinical practice in a large cohort of consecutive, unselected patients with newly diagnosed MM and looked at the major determinants of response of patients enrolled in a HDT with tandem autotransplantation (Total Therapy I, TTI) program. DESIGN AND METHODS: Two hundred and fourteen patients were treated outside of a clinical trial and regularly followed-up at our Center for symptomatic MM. Ninety-seven patients (45%) received conventional chemo-radiotherapy regimens, 110 (51%) entered the TTI program and the remaining 7 patients (3.3%) were enrolled in other programs involving HDT with autotransplantation. RESULTS: Patients enrolled in HDT with tandem autotransplantation programs were 14 years younger and less likely to have co-morbidities than patients treated with conventional therapy. Median overall survivals of the two groups were 60 and 33 months, respectively. Thirteen percent of the patients enrolled in the TTI program did not receive the first HDT with autotransplantation, mostly because of disease progression, and another 16% did not proceed to the second HDT with autotransplantation mainly because of infections or drug-related complications. Most patients achieved complete remission after the second autotransplantation, with acceptable toxicity. However, only patients with a major reduction of the myeloma burden at the end of induction therapy enjoyed significantly prolonged event-free and overall survivals. INTERPRETATION AND CONCLUSIONS: Approximately one third of patients with newly diagnosed symptomatic MM completed the TTI program. These data suggest the need to improve the induction therapy in order to increase both the number of patients able to proceed to autotransplantation programs and to enhance the rate of early response.


This article has been cited by other articles:


Home page
 JCOHome page
J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
J. Clin. Oncol., December 10, 2008; 26(35): 5775 - 5782.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.